- Home
- BRT vs BNTC Comparison
BRT vs BNTC Comparison
Compare BRT & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | BNTC |
|---|---|---|
| Founded | 1972 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.9M | 405.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BRT | BNTC |
|---|---|---|
| Price | $14.73 | $13.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $19.75 | ★ $27.67 |
| AVG Volume (30 Days) | 62.1K | ★ 245.8K |
| Earning Date | 11-06-2025 | 02-13-2026 |
| Dividend Yield | ★ 6.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,001,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $14.00 | $9.70 |
| 52 Week High | $19.01 | $17.15 |
Technical Indicators
Market Signals| Indicator | BRT | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 55.22 |
| Support Level | $14.18 | $10.99 |
| Resistance Level | $15.33 | $13.36 |
| Average True Range (ATR) | 0.28 | 0.93 |
| MACD | -0.02 | 0.20 |
| Stochastic Oscillator | 50.43 | 94.82 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.